Charles B. Nemeroff, MD, PhD
Matthew P. Nemeroff Professor and Chair
Department of Psychiatry and Behavioral Sciences
Mulva Clinic for the Neurosciences
Director, Institute of Early Life Adversity Research
Dell Medical School, The University of Texas at Austin
Charles B. Nemeroff is currently the Matthew P. Nemeroff Professor and Chair, Department of Psychiatry and Behavioral Sciences and Director, Institute for Early Life Adversity Research and Co-Director of the Center for Psychedelic Research and Therapy at the University of Texas at Austin, Dell Medical School in Austin, Texas. Previously, Dr. Nemeroff was the Leonard M. Miller Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine. He is past president of the American College of Psychiatrists and the American College of Neuropsychopharmacology. His research has focused on the neurobiology of mood and anxiety disorders with a focus on the long term consequences of child abuse and neglect and how these changes increase vulnerability for psychiatric and medical disorders in adulthood. He has published more than 1100 research reports and reviews, and 17 books. He is a member of the Institute of Medicine of the National Academy of Medicine(USA). n 2023 Dr. Nemeroff was ranked #238 in the world ranking and #159 in United States by Research.com, a leading academic platform for researchers.
Dr. Nemeroff has been an ADAA member since 1999, was elected ADAA Chief Medical Officer in March, 2019 and is currently Board President.
ADAA is a wonderful organization dedicated to the improvement of treatment of mood and anxiety disorders. I have had the privilege of being a part of ADAA for many years and having the honor to serve as president is a highlight of my career. The collegiality of practitioners and scientists dedicated to the improvement of patient care for these devastating disorders combined with the adherence to evidence-based research and treatment makes ADAA a wonderful environment for clinicians and investigators. I look forward to hearing from ADAA members with their thoughts about how to make our beloved organization even better.